Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Outstanding (Diluted Average) (2018 - 2025)

Kiora Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 8 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 0.51% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $4.1 million, down 0.51%, while the annual FY2025 figure was $4.1 million, 0.51% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $4.1 million in Q4 2025 per KPRX's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $13.1 million in Q2 2022 to a low of $212612.0 in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $3.5 million, with a median of $3.9 million recorded in 2025.
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 97.2% in 2023, then skyrocketed 1040.98% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $241099.0 in 2021, then soared by 251.94% to $848534.0 in 2022, then tumbled by 36.6% to $538007.0 in 2023, then soared by 666.73% to $4.1 million in 2024, then decreased by 0.51% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Shares Outstanding (Diluted Average) are $4.1 million (Q4 2025), $4.4 million (Q3 2025), and $3.9 million (Q2 2025).